Navigation Links
Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH

e list of worldwide patient associations and professional health organizations and additional sources of information.

###

References 1. Nick H & Kim S. Assessment of Operability in Chronic Thromboembolic Pulmonary Hypertension. Proc AmThorac Soc 2006; 3: 584-588 2. Dartevelle P et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:637-648. 3. LJ Rubin et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896-903 4. Tracleer® SPC Actelion Ltd Actelion Ltd. is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. At the end of September 2006, Tracleer® was commercially available in 35 countries worldwide. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 1,200 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN). For further information please contact: Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil Investor Contact Roland Haefeli +41 61 565 64 58 +1 650 624 6936 Media Contact Peter Engel +41 61 565 66 28 +1 650 624 6996 http://www.actelion.com Conference Call Actelion will host an Investor Conference Call and discussion/Q&A on Monday, 5 March 2007, 07.45 CET / 01.45 AM EST / 06.45 GMT Dial: +41 (0)91 610 56 00 (Europe) +1 (1) 866 291 4166 (U.S.
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Actelion Announces Positive Study with Bosentan Tracleer CTEPH
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... INDIANAPOLIS, Jan. 18, 2011 Eli Lilly and Company (NYSE: ... the fourth quarter and full year of 2010 on Thursday, ... on that day with the investment community and media to ... conference call will be held from 9:00 a.m. to 10:00 ...
... Jan. 18, 2011 DW Healthcare Partners (DWHP), a ... announced the appointment of Bradley Lanham as the new ... DWHP has now completed acquisitions of institutional pharmacies specializing ... including Texas, Nevada, Utah, Idaho and Colorado. ...
Cached Medicine Technology:DW Healthcare Partners Announces New CEO on Heels of Increased Investment in Institutional Pharmacy Sector 2
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... Viejo, California (PRWEB) December 25, 2014 ... release of ProFire 5k. A fully customizable business presentation ... . , “Adding the ProFire 5k business tool, users ... Said Christina Austin, CEO of Pixel Film Studios. “ProFire ... look and style to add professionalism to a presentation” ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... is 700 smiling little faces this holiday that might ... in monetary donations was given to the various charities ... they incur through the year. Some of the charities ... Haven , Shrine's Children's Hospitals, Toys for Tots and ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2
... - Estimated one-year, recurrence-free survival was 98% for Kit-positive ... placebo(1)- Historically, one in two patients experienced recurrence of ... - Gleevec is the only treatment in the US ... GIST after surgery; regulatory review is underway in the ...
... , Men with a limited life expectancy due to advanced age and existing medical conditions may not ... , Click here for more ... , , , ... , , ...
... Carry Extreme Physical Performance Products Including ANABEUTROL and ... March 18 Extreme Physical Performance is proud ... Nutrition Centers in an aggressive movement to increase ... ANABEUTROL(TM) and ANDRITEST(TM). GNC,s specialty retail locations number ...
... CHERRY HILL, N.J., March 18 Subaru of America, ... Edition to the Ronald McDonald House (RMH) of Southern ... Outback, valued at approximately $26,000, will be used to ... illnesses or traumatic injuries. The vehicle will also be ...
... EMERYVILLE, Calif., March 18 Bionovo, Inc. (Nasdaq: ... the unmet needs in women,s health and oncology, today announced ... presenting at the Wall Street Analyst Forum,s 20th Annual Institutional ... The event will be held at the University Club ...
... obesity, study found , , WEDNESDAY, March 18 (HealthDay News) -- ... whites, a long-running study shows. , "What we found is ... it is not a rare occurrence," said Dr. Kirsten Bibbins-Domingo, ... of the New England Journal of Medicine . "It ...
Cached Medicine News:Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 2Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 3Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 4Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 5Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 6Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 7Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 8Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 9Health News:US trial shows no early mortality benefit from annual prostate cancer screening 2Health News:US trial shows no early mortality benefit from annual prostate cancer screening 3Health News:US trial shows no early mortality benefit from annual prostate cancer screening 4Health News:US trial shows no early mortality benefit from annual prostate cancer screening 5Health News:US trial shows no early mortality benefit from annual prostate cancer screening 6Health News:Innovative Sports Supplement Firm Muscles Up to General Nutrition Centers in a New National Partnership 2Health News:Subaru of America Donates New Outback to Aid Ronald McDonald House Families 2Health News:Subaru of America Donates New Outback to Aid Ronald McDonald House Families 3Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 2Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 3Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 4Health News:High Rate of Early Heart Failure Seen in Blacks 2Health News:High Rate of Early Heart Failure Seen in Blacks 3
... This requiring no water ... long-lasting hand hygiene to physically ... washing is either not an ... Hibistat allows you to return ...
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... The Scrub Care® Brand soaps, emulsions, ... the ultimate in healthy skin care, ... keeping skin healthy and soft even ... do not contain petroleum-based substances that ...
... Scrub Care Scrub Brushes & ... choices to meet the demanding needs ... a preimpregnated scrub brush or prefer ... with bottled antimicrobial solution, scrub brushes ...
Medicine Products: